Mark drove from the Netherlands to Norway to save Misty with a new cancer treatment
Lovely article from forskning.no detailing how our research has been brought to life in the clinic. Together with our veterinarian partners at […]
Lung metastasis – Patient recruitment
Alv B, in co-operation with the Veterinary School at the Norwegian Life Science University (NMBU) has cleared the regulatory requirements
Alv B receives study approval for Alvacan 4000
We have received approval from The Norwegian Food Safety Authority (Mattilsynet) to test our Alvacan 1000 and 4000 immune cell-based
Alv B AS files for patent protection on cancer vaccine technology
Today, we have filed for patent protection for our innovative cancer vaccine technology. In cooperation with the patent attorney office,
Alv B AS partners with Oncogene AS to identify canine gene targets for cancer vaccine development.
Alv B AS is excited to announce that our collaboration with Oncogene AS, a Norwegian cancer precision medicine & informatics initiative.
Alv B AS is happy to announce its collaboration with Diakonos Oncology Corporation.
Alv B has signed a licensing agreement with Diakonos for exclusive rights of Tumor Prep in the European market, with
Alv B announces co-operation with AJ Vaccines for cancer vaccines
AJ Vaccines lends support to Alv B for upcoming cancer vaccine trial in dogs, by supplying key component free of
Francesca Lockwood joins the team
Francesca Lockwood is a London native, with an educational background comprised of a first-class BSc in Pharmacology, an Erasmus placement,
Steven Verhaegen joins the team
Steven gained his Licentiaat in Biological Sciences at the Free University of Brussels, Belgium in 1985. He was a European
FRANCESCA GATTI JOINS THE TEAM
Francesca Gatti er Industrial Scientist i ALV B. Hun er celle- og molekylærbiolog med PhD i Bioteknologi med fokus på